S2MEDICAL AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0375 SEK | -2.60% |
|
+7.14% | -37.50% |
| 05-17 | S2Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-20 | S2Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 344.5 | 107.1 | 90.36 | 79.02 | 22.09 | 16.53 |
| Enterprise Value (EV) 1 | 310.3 | 93.12 | 66.05 | 69.75 | 18.37 | 15.01 |
| P/E ratio | -16.1 x | -5.81 x | -6.25 x | -3.88 x | -0.55 x | -0.32 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 84.1 x | 19.1 x | 3.28 x | 7.21 x | 3.59 x | 2.14 x |
| EV / Revenue | 75.8 x | 16.6 x | 2.4 x | 6.36 x | 2.98 x | 1.94 x |
| EV / EBITDA | -30.5 x | -5.34 x | -4.71 x | -3.72 x | -0.7 x | -1.06 x |
| EV / FCF | -29.6 x | -6.98 x | -9.9 x | -9.16 x | -1.12 x | -1.37 x |
| FCF Yield | -3.38% | -14.3% | -10.1% | -10.9% | -89.2% | -73.2% |
| Price to Book | 7.91 x | 4.26 x | 3.61 x | 5.38 x | 3.13 x | 9.97 x |
| Nbr of stocks (in thousands) | 11,295 | 11,295 | 11,295 | 15,052 | 32,492 | 275,452 |
| Reference price 2 | 30.50 | 9.480 | 8.000 | 5.250 | 0.6800 | 0.0600 |
| Announcement Date | 4/25/19 | 4/24/20 | 4/26/21 | 4/26/22 | 5/10/23 | 5/9/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4.095 | 5.599 | 27.53 | 10.96 | 6.159 | 7.724 |
| EBITDA 1 | -10.17 | -17.45 | -14.03 | -18.73 | -26.37 | -14.14 |
| EBIT 1 | -10.61 | -18.33 | -14.94 | -19.84 | -27.69 | -15.26 |
| Operating Margin | -259.04% | -327.45% | -54.25% | -180.99% | -449.53% | -197.63% |
| Earnings before Tax (EBT) 1 | -10.73 | -18.44 | -15.01 | -20.08 | -29.46 | -22.71 |
| Net income 1 | -10.73 | -18.44 | -15.01 | -20.08 | -29.46 | -22.71 |
| Net margin | -262.07% | -329.26% | -54.52% | -183.21% | -478.23% | -294% |
| EPS 2 | -1.899 | -1.632 | -1.279 | -1.354 | -1.239 | -0.1869 |
| Free Cash Flow 1 | -10.48 | -13.34 | -6.674 | -7.614 | -16.38 | -10.99 |
| FCF margin | -255.92% | -238.18% | -24.24% | -69.47% | -265.95% | -142.25% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/25/19 | 4/24/20 | 4/26/21 | 4/26/22 | 5/10/23 | 5/9/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 34.2 | 14 | 24.3 | 9.27 | 3.72 | 1.52 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -10.5 | -13.3 | -6.67 | -7.61 | -16.4 | -11 |
| ROE (net income / shareholders' equity) | -42.1% | -53.7% | -51.9% | -84.3% | -271% | -520% |
| ROA (Net income/ Total Assets) | -22% | -28.7% | -25.9% | -34.9% | -63% | -40.9% |
| Assets 1 | 48.77 | 64.19 | 57.84 | 57.61 | 46.78 | 55.58 |
| Book Value Per Share 2 | 3.860 | 2.220 | 2.220 | 0.9800 | 0.2200 | 0.0100 |
| Cash Flow per Share 2 | 3.230 | 1.370 | 1.700 | 0.6300 | 0.1100 | 0.0100 |
| Capex | - | 0.64 | 0.06 | 0.19 | 0.11 | - |
| Capex / Sales | - | 11.52% | 0.23% | 1.71% | 1.78% | - |
| Announcement Date | 4/25/19 | 4/24/20 | 4/26/21 | 4/26/22 | 5/10/23 | 5/9/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -37.50% | 1.01M | |
| -5.94% | 180B | |
| -3.00% | 105B | |
| -4.32% | 67.27B | |
| -5.68% | 46.34B | |
| +14.66% | 46.22B | |
| +4.14% | 40.1B | |
| +20.04% | 30.92B | |
| -4.95% | 24.48B | |
| +12.05% | 24.22B |
- Stock Market
- Equities
- S2M Stock
- Financials S2Medical AB
